Meridian Bioscience, Inc. (VIVO) Given Consensus Recommendation of “Hold” by Analysts
Meridian Bioscience, Inc. (NASDAQ:VIVO) has received an average recommendation of “Hold” from the six research firms that are currently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation and four have given a hold recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $11.50.
VIVO has been the topic of a number of analyst reports. BidaskClub cut shares of Meridian Bioscience from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 2nd. Zacks Investment Research cut shares of Meridian Bioscience from a “hold” rating to a “sell” rating in a report on Tuesday, October 24th. Finally, Canaccord Genuity reissued a “hold” rating and set a $14.00 target price on shares of Meridian Bioscience in a report on Friday, October 13th.
In related news, Chairman John A. Kraeutler bought 7,000 shares of the business’s stock in a transaction that occurred on Thursday, August 24th. The stock was bought at an average cost of $13.67 per share, for a total transaction of $95,690.00. Following the completion of the transaction, the chairman now owns 345,230 shares of the company’s stock, valued at $4,719,294.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 2.30% of the company’s stock.
Shares of Meridian Bioscience (VIVO) opened at $14.95 on Friday. The company has a quick ratio of 4.42, a current ratio of 6.47 and a debt-to-equity ratio of 0.31. The company has a market cap of $630.94, a P/E ratio of 21.91 and a beta of 0.89. Meridian Bioscience has a 1-year low of $10.75 and a 1-year high of $18.58.
Meridian Bioscience (NASDAQ:VIVO) last posted its quarterly earnings results on Thursday, November 9th. The company reported $0.15 EPS for the quarter, hitting analysts’ consensus estimates of $0.15. The company had revenue of $49.70 million for the quarter, compared to analysts’ expectations of $48.28 million. Meridian Bioscience had a net margin of 10.74% and a return on equity of 17.07%. Meridian Bioscience’s revenue was up 5.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.14 EPS. analysts expect that Meridian Bioscience will post 0.66 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, November 30th. Stockholders of record on Monday, November 20th will be issued a $0.125 dividend. The ex-dividend date of this dividend is Friday, November 17th. This represents a $0.50 annualized dividend and a dividend yield of 3.34%. Meridian Bioscience’s payout ratio is currently 98.04%.
Meridian Bioscience Company Profile
Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.
Receive News & Stock Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related stocks with our FREE daily email newsletter.